Kura Oncology (KURA) AI Stock Analysis

• Market Cap: $830.15M
• Dividend Yield: N/A
• Average Volume (3M): 1.47M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.45
• Revenue Growth: N/A
• EPS Growth: -5.18%
• Country: US
• Employees: 192
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.85
• Shares Outstanding: 87,017,520
• 10 Day Avg. Volume: 975,643
• 30 Day Avg. Volume: 1,468,772
• PEG Ratio: 1.50
• Price to Book (P/B): 1.81
• Price to Sales (P/S): 13.93
• P/FCF Ratio: 5.61
• Enterprise Value/Market Cap: 0.30
• Enterprise Value/Revenue: 2.36
• Enterprise Value/Gross Profit: 2.43
• Enterprise Value/Ebitda: -1.11
• 1Y Price Target: $29.71
• Price Target Upside: 211.43% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: $11.00 ▲(15.30% Upside)

The score is led by strong recent clinical/regulatory execution and commercialization milestones (FDA approval and first U.S. sale with a $135M payment), supported by reported cash runway through 2027. Offsetting this are still-large operating losses, shrinking equity, and only mixed near-term technical momentum, while valuation metrics are not very informative due to negative earnings.

Positive Factors

NDA Submission

The NDA submission for ziftomenib marks a critical milestone in Kura's clinical development, potentially accelerating market entry and revenue generation if approved.

Strong Financial Position

A robust cash position provides Kura with the financial flexibility to fund ongoing R&D and clinical trials, supporting long-term strategic initiatives and growth.

Clinical Trial Progress

Progress in clinical trials, including data presentations, enhances Kura's pipeline credibility and potential for successful drug development, driving future growth.

Negative Factors

Increased R&D Expenses

Rising R&D expenses reflect higher costs in advancing the pipeline, which could pressure margins and extend the timeline to profitability if not managed effectively.

Net Loss

Ongoing net losses highlight profitability challenges, common in biotech, which may impact long-term financial health and necessitate further financing.

Trial Response Challenges

Challenges in achieving high response rates in trials may affect the perceived efficacy of drug candidates, impacting regulatory approval prospects and market potential.

Kura Oncology Business Overview & Revenue Model

Company Description

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

How the Company Makes Money

Kura Oncology generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company finances its operations through public offerings, partnerships, and collaborations with other pharmaceutical companies. Kura's earnings are significantly influenced by milestone payments and potential royalties from licensing agreements as its drug candidates progress through clinical trials and, if successful, receive regulatory approval. Additionally, the company may engage in strategic partnerships to co-develop or out-license its therapies, which can provide upfront payments and shared revenue streams from eventual product sales.

Kura Oncology Financial Statement Overview

Summary

Kura Oncology is experiencing revenue growth, yet profitability remains a challenge with negative margins. Strong liquidity is offset by historical financial distress and high leverage. Cash flow management shows improvement, but overall financial health is impacted by ongoing losses.

Income Statement

Kura Oncology showed positive revenue growth in TTM, moving from no revenues to generating income. However, margins remain negative with a net profit margin of -267.57% and an EBIT margin of -299.21%, reflecting ongoing profitability challenges common in early-stage biotech companies.

Balance Sheet

The company maintains strong liquidity with significant cash reserves but faces high leverage with a debt-to-equity ratio of 0.03. The equity ratio at 48.98% indicates moderate financial stability, yet the negative equity in prior years signals historical financial distress.

Cash Flow

Kura Oncology shows a slight improvement in cash flow management with positive operating cash flow in the TTM. The free cash flow to net income ratio is strong despite negative net income, indicating efficient cash management amidst ongoing losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	104.03M	53.88M	0.00	0.00	0.00	0.00
Gross Profit	100.82M	53.88M	-849.00K	0.00	0.00	-194.00K
EBITDA	-220.75M	-169.50M	-150.23M	-134.85M	-129.49M	-88.85M
Net Income	-216.88M	-173.98M	-152.63M	-135.84M	-130.47M	-89.63M
Balance Sheet
Total Assets	649.38M	760.16M	448.94M	456.31M	534.05M	647.21M
Cash, Cash Equivalents and Short-Term Investments	549.66M	727.39M	423.96M	437.99M	517.96M	633.32M
Total Debt	19.47M	16.59M	17.20M	14.02M	6.88M	14.98M
Total Liabilities	406.84M	346.52M	51.66M	36.03M	27.44M	36.31M
Stockholders Equity	242.54M	413.64M	397.27M	420.28M	506.61M	610.90M
Cash Flow
Free Cash Flow	83.11M	133.84M	-124.99M	-110.69M	-105.70M	-72.00M
Operating Cash Flow	87.80M	134.32M	-124.82M	-110.06M	-104.55M	-69.83M
Investing Cash Flow	-43.46M	-101.59M	15.56M	32.63M	-126.83M	-99.94M
Financing Cash Flow	1.46M	154.42M	94.78M	38.56M	-3.44M	469.33M

Kura Oncology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.54
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KURA, the sentiment is Negative. The current price of 9.54 is below the 20-day moving average (MA) of 10.45, below the 50-day MA of 10.72, and above the 200-day MA of 7.94, indicating a neutral trend. The MACD of -0.25 indicates Positive momentum. The RSI at 38.82 is Neutral, neither overbought nor oversold. The STOCH value of 19.21 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KURA.

Kura Oncology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KROS	72 Outperform	$545.95M	11.53	10.43%	―	37798.31%	―
PHAT	67 Neutral	$1.13B	-4.29	―	―	460.30%	33.03%
KURA	63 Neutral	$830.15M	-3.85	-65.10%	―	―	-5.18%
SEPN	61 Neutral	$1.20B	-16.85	-22.38%	―	2147.20%	-269.99%
TYRA	57 Neutral	$1.40B	-14.04	-34.75%	―	―	-17.01%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ORKA	41 Neutral	$1.30B	-11.01	-23.05%	―	―	63.85%

Kura Oncology Corporate Events

Kura Oncology Announces First U.S. Sale of KOMZIFTI

On December 2, 2025, Kura Oncology announced the first U.S. commercial sale of KOMZIFTI™ (ziftomenib), following its FDA approval on November 13, 2025. This milestone sale triggers a $135 million payment from their partner, Kyowa Kirin, which Kura Oncology expects to receive before the end of the year, marking a significant financial boost and strategic advancement in their market positioning.

The most recent analyst rating on (KURA) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Kura Oncology stock, see the KURA Stock Forecast page.

Kura Oncology Gains FDA Approval for KOMZIFTITM

On November 13, 2025, Kura Oncology and Kyowa Kirin announced the FDA’s full approval of KOMZIFTITM (ziftomenib) for adult patients with relapsed or refractory acute myeloid leukemia with an NPM1 mutation. This approval marks a significant advancement as KOMZIFTI is the first oral menin inhibitor for this type of AML, addressing a critical need for effective treatments. The approval is based on the KOMET-001 trial, which demonstrated a complete remission rate of 21.4% in patients. The strategic collaboration between Kura Oncology and Kyowa Kirin, established in November 2024, positions the companies to leverage their combined expertise in hematologic malignancies for the development and commercialization of KOMZIFTI, with Kura leading efforts in the U.S. and Kyowa Kirin outside the U.S.

The most recent analyst rating on (KURA) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Kura Oncology stock, see the KURA Stock Forecast page.

Kura Oncology Receives $30M Milestone Payment

On October 24, 2025, Kura Oncology announced a $30 million milestone payment from Kyowa Kirin following the dosing of the first patient in the KOMET-017 Phase 3 trials for ziftomenib, an investigational oral menin inhibitor. This development marks a significant step in evaluating ziftomenib’s efficacy in treating acute myeloid leukemia, potentially enhancing Kura Oncology’s market position and offering new hope for patients with NPM1-mutated or KMT2A-rearranged conditions.

The most recent analyst rating on (KURA) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Kura Oncology stock, see the KURA Stock Forecast page.

Kura Oncology Expands Inducement Option Plan Shares

On October 15, 2025, Kura Oncology‘s Board of Directors approved an amendment to the company’s 2023 Inducement Option Plan, increasing the reserved shares to 3,250,000. This amendment aims to attract new talent by offering nonstatutory stock options as an inducement for employment, enhancing the company’s ability to recruit skilled individuals and potentially strengthening its market position.

The most recent analyst rating on (KURA) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Kura Oncology stock, see the KURA Stock Forecast page.